JPMA to Ponder Pricing System for New Modalities towards 2026 Reform: Chief

JPMA President Hiroaki Ueno The Japan Pharmaceutical Manufacturers Association (JPMA) will discuss ways to craft a drug pricing system that appropriately reflects the value of new modalities in preparation for the FY2026 reimbursement reform, President Hiroaki Ueno said on February...read more